Vesugen
A short peptide bioregulator studied by its original developers for vascular tissue.
Research Use Only — Not for Human ConsumptionShort Description
Vesugen is a short synthetic peptide from the family of "peptide bioregulators" originally developed by Russian researchers (the Khavinson peptide series), associated in that research tradition with blood vessel tissue.
Current Legal Status (Mauritius)
Tiger Blood Pharmaceuticals is pursuing product registration in the Republic of Mauritius, where pharmaceutical products are regulated by the Pharmacy Board, operating under the Ministry of Health and Wellness pursuant to the Pharmacy Act 1983. Vesugen is not currently registered as a pharmaceutical product in Mauritius, and our registration application has not yet been completed. Until registration is granted, Vesugen is supplied strictly for laboratory research use and is not sold, marketed or labeled as a medicine, supplement or treatment for any condition in any jurisdiction.
Tiger Blood Pharmaceuticals does not hold regulatory approval for Vesugen in the United States, the European Union, the United Kingdom, or any other jurisdiction. Because this website is publicly accessible, customers are responsible for confirming that the purchase, import and use of this product is lawful where they live before placing an order.
This page will be updated once our Mauritius registration status changes.
Research Evidence
Published research on Vesugen is limited in volume and comes largely from its original developers, with little independent replication in Western peer-reviewed literature. It has not been evaluated by the FDA, EMA or comparable regulators.